Maker Of Coronavirus Trial Drug Remdesivir, Gilead Sciences. Inc., Reports Positive Data Coming From Trials

Justin Sullivan

Gilead (NASDAQ:GILD) had little motion for many of 2022, however rallied considerably following robust Q3 outcomes, reported on October twenty seventh. Due to this surge, GILD has a trailing 12-month whole return of 26.7%, as in comparison with

price history

In search of Alpha

earnings history

ETrade

Wall Street consensus outlook

In search of Alpha

market-implied outlook

Writer’s calculations utilizing choices quotes from ETrade

market-implied outlook

Writer’s calculations utilizing choices quotes from ETrade

market-implied outlook

Writer’s calculations utilizing choices quotes from ETrade



Source link